Ellevest Inc. decreased its holdings in AstraZeneca PLC (NASDAQ:AZN - Free Report) by 24.0% in the 4th quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 16,093 shares of the company's stock after selling 5,080 shares during the quarter. Ellevest Inc.'s holdings in AstraZeneca were worth $1,054,000 as of its most recent filing with the SEC.
Other large investors also recently bought and sold shares of the company. Capital International Investors increased its position in AstraZeneca by 1.9% during the 4th quarter. Capital International Investors now owns 37,507,159 shares of the company's stock worth $2,457,706,000 after purchasing an additional 686,008 shares in the last quarter. Bank of America Corp DE raised its holdings in shares of AstraZeneca by 189.3% during the 4th quarter. Bank of America Corp DE now owns 24,026,966 shares of the company's stock valued at $1,574,247,000 after buying an additional 15,722,197 shares during the period. Franklin Resources Inc. increased its holdings in AstraZeneca by 1.9% during the 4th quarter. Franklin Resources Inc. now owns 19,480,569 shares of the company's stock worth $1,276,367,000 after purchasing an additional 357,894 shares during the last quarter. Jennison Associates LLC increased its holdings in AstraZeneca by 3.1% during the 4th quarter. Jennison Associates LLC now owns 15,430,963 shares of the company's stock worth $1,011,037,000 after purchasing an additional 466,416 shares during the last quarter. Finally, Sanders Capital LLC increased its holdings in shares of AstraZeneca by 1.4% in the 4th quarter. Sanders Capital LLC now owns 15,186,692 shares of the company's stock valued at $995,032,000 after acquiring an additional 212,301 shares during the last quarter. Institutional investors and hedge funds own 20.35% of the company's stock.
AstraZeneca Stock Down 2.1%
NASDAQ:AZN traded down $1.44 during trading hours on Wednesday, hitting $66.28. 3,854,350 shares of the company's stock traded hands, compared to its average volume of 5,153,859. The firm has a market cap of $205.55 billion, a P/E ratio of 29.33, a P/E/G ratio of 1.42 and a beta of 0.40. AstraZeneca PLC has a twelve month low of $61.24 and a twelve month high of $87.68. The company has a debt-to-equity ratio of 0.65, a quick ratio of 0.74 and a current ratio of 0.93. The stock's fifty day moving average price is $70.96 and its two-hundred day moving average price is $69.60.
AstraZeneca (NASDAQ:AZN - Get Free Report) last posted its quarterly earnings results on Tuesday, April 29th. The company reported $1.24 earnings per share for the quarter, beating the consensus estimate of $1.10 by $0.14. AstraZeneca had a return on equity of 32.23% and a net margin of 13.01%. The firm had revenue of $13.59 billion for the quarter, compared to analyst estimates of $13.71 billion. During the same period in the previous year, the firm earned $2.06 earnings per share. AstraZeneca's quarterly revenue was up 7.2% on a year-over-year basis. On average, research analysts expect that AstraZeneca PLC will post 4.51 earnings per share for the current fiscal year.
Analyst Upgrades and Downgrades
A number of research firms recently issued reports on AZN. BNP Paribas assumed coverage on AstraZeneca in a research report on Tuesday, April 15th. They set an "outperform" rating and a $75.00 price objective for the company. UBS Group upgraded AstraZeneca from a "neutral" rating to a "buy" rating in a report on Thursday, February 13th. Finally, Morgan Stanley initiated coverage on AstraZeneca in a report on Wednesday, February 12th. They issued an "overweight" rating for the company. One analyst has rated the stock with a hold rating, seven have issued a buy rating and two have given a strong buy rating to the stock. According to data from MarketBeat.com, AstraZeneca currently has a consensus rating of "Buy" and an average price target of $88.00.
Get Our Latest Analysis on AstraZeneca
AstraZeneca Profile
(
Free Report)
AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines. The company's marketed products include Tagrisso, Imfinzi, Lynparza, Calquence, Enhertu, Orpathys, Truqap, Zoladex, Faslodex, Farxiga, Brilinta, Lokelma, Roxadustat, Andexxa, Crestor, Seloken, Onglyza, Bydureon, Fasenra, Breztri, Symbicort, Saphnelo, Tezspire, Pulmicort, Bevespi, and Daliresp for cardiovascular, renal, metabolism, and oncology.
Featured Stories
Before you consider AstraZeneca, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and AstraZeneca wasn't on the list.
While AstraZeneca currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Nuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
